

## Cobalamin derivatives

Patent Number: GB944428

Publication date: 1963-12-11

Inventor(s):

Applicant(s): MERCK & CO INC

Requested Patent:  GB944428

Application Number: GB19600011585 19600401

Priority Number(s): US19590804145 19590406

IPC Classification:

EC Classification: C07H23/00C

Equivalents:  CH385873,  SE304004

### Abstract

The Specification comprises amino acid cobalamins of which those derived from glycine, lysine, aspartic acid, alanine, serine, cysteine, phenylalanine, tryptophane, histidine, methionine, valine, leucine, arginine, glutamic acid, and proline are specified. These compounds may be prepared by intimately contacting hydroxocobalamin and an amino acid in aqueous solution and then adding acetone to precipitate the product in crystalline form, alternatively the aqueous solution is evaporated by freeze drying. The compounds may be mixed with a solid carrier such as lactose, starch, sugar, stearic acid, magnesium stearate or gelatin or with a liquid such as water or benzyl alcohol to give compositions which give high prolonged serum levels on administration. ALSO: A medicinal preparation comprises an amino acid cobalamin and a pharmacologically acceptable carrier therefor. Specified cobalamins are those derived from glycine, lysine, aspartic acid, alanine, serine, cysteine, phenylalanine, tryptophane, histidine, methionine, valine, leucine, arginine, glutamic acid and proline; and they may be made according to the method described in Division C2. The carrier may be lactose, starch, sugar, stearic acid, magnesium stearate, or gelatin, or a liquid such as water or benzyl alcohol. The compositions may be made up in dosage units of 1 to 2500 mlg. of cobalamin activity.

Data supplied from the esp@cenet database - I2

BEST AVAILABLE COPY

944,428



# PATENT SPECIFICATION

NO DRAWINGS

944,428

Date of Application and filing Complete Specification: April 1, 1960.

No. 11585/60.

Application made in United States of America (No. 804,145) on April 6, 1959.

Complete Specification Published: Dec. 11, 1963.

© Crown Copyright 1963.

Index at acceptance:—Classes C2, V6; A5, B(2G, 2S).

International Classification:—C 07 d (A 61 k).

## COMPLETE SPECIFICATION

### Cobalamin Derivatives

We, MERCK & CO. INC., a corporation duly organised and existing under the laws of the State of New Jersey, United States of America, of Rahway, State of New Jersey, United States of America, do hereby declare the invention, for which we pray that a patent may be granted to us, and the method by which it is to be performed, to be particularly described in and by the following statement:—

This invention relates to cobalamin derivatives. More particularly it provides amino acid cobalamins, methods of preparing these cobalamin derivatives and compositions containing these cobalamin derivatives.

Vitamin B—12, which is also called cyanocobalamin, is known to be essential for erythrocyte maturation, and therapy with cyanocobalamin is indicated in anaemias resulting from its improper absorption and utilization. Thus, in the treatment of pernicious anaemia, cyanocobalamin is administered parenterally by subcutaneous or intramuscular injections. For this purpose aqueous solutions of vitamin B—12 in suitable vehicles are used. However, improved forms of cobalamin which would provide higher serum levels of cobalamin have been sought.

It is an aim of the present invention to provide improved cobalamin products producing higher serum levels of cobalamin on administration.

It has now been found that amino acid cobalamins are valuable sources of cobalamin activity and possess the unexpected advantage that they are absorbed to a greater extent than cyanocobalamin. Thus, clinical tests show that these cobalamins give higher blood levels upon administration, and also apparently give higher prolonged serum levels of cobalamin.

There is therefore provided, according to the invention, a composition comprising an amino acid cobalamin and a pharmacologically acceptable carrier therefor.

The amino acid cobalamins are conveniently

prepared by intimately contacting hydroxocobalamin and an amino acid in an aqueous solution. In general, the amino acid cobalamin compound is readily recovered from the resulting reaction mixture by adding a suitable miscible solvent such as acetone whereby the cobalamin precipitates from the solution in crystalline form and can be readily recovered, as for example by filtration. Alternatively, the amino acid cobalamin compound is recovered by evaporating the aqueous solution containing the molar equivalents of hydroxocobalamin and the amino acid, as for example by freeze drying.

Thus, in brief, there is provided according to the invention a process for preparing an amino acid cobalamin which comprises intimately contacting hydroxocobalamin and an amino acid in aqueous solution and recovering the amino acid cobalamin from the reaction mixture.

The following examples are illustrative of the methods by which these amino acid cobalamin compounds can be prepared:

#### EXAMPLE I Glycine cobalamin

Hydroxocobalamin in an amount equivalent to 200 mg. of anhydrous weight, was dissolved in 40 ml. of water. To this solution was added 12.5 mg. of glycine. 375 ml. of acetone was added and the product allowed to crystallize. The crystals were isolated by filtration and dried *in vacuo* at room temperature. The product, which weighed 125 mg., contained 7.5 per cent volatiles and assayed 86.5 percent Vitamin B—12 (anhydrous basis) by isotope dilution assay. When correction is made for ratio of the molecular weights of cyanocobalamin and the glycine cobalamin the purity is *ca.* 90 per cent.

In a similar manner aspartic acid cobalamin is prepared by combining aspartic acid and hydroxocobalamin in aqueous solution and adding acetone.

50

55

60

65

70

75

80

85

# RESERVE COPY

## PATENT SPECIFICATION

**944,428**



NO DRAWINGS

**944,428**

*Date of Application and filing Complete Specification: April 1, 1960.*

*No. 111585/60.*

*Application made in United States of America (No. 804,145) on April 6, 1959.*

*Complete Specification Published: Dec. 11, 1963.*

*© Crown Copyright 1963.*

**Index at acceptance:—Classes C2, V6; A5, B(2G, 2S).**

**International Classification:—C 07 d (A 61 k).**

### COMPLETE SPECIFICATION

#### Cobalamin Derivatives

#### ERRATA

**SPECIFICATION No. 944,428**

- Page 1, lines 48 and 55, for "cobalamin"  
read "cobalamin"  
Page 2, line 11, for "cadculated" read "cal-  
culated"  
Page 2, line 51, for "lactoose" read "lactose"  
Page 3, 1st Table, for "Cyanocabalamin"  
read "Cyanocobalamin"

THE PATENT OFFICE  
*19th October 1964*

xo-  
ous  
nin  
ult-  
ible 50  
the  
in  
ted,  
ely,  
re-  
tion  
xo-  
iple

ling 60  
an  
nti-  
an  
ring

65

the amino acid cobalamins from the reaction  
mixture.

The following examples are illustrative of  
the methods by which these amino acid cob-  
alamin compounds can be prepared:

#### EXAMPLE I Glycine cobalamin

Hydroxocobalamin in an amount equivalent  
to 200 mg. of anhydrous weight, was dissolved  
in 40 ml. of water. To this solution was added  
12.5 mg. of glycine. 375 ml. of acetone was  
added and the product allowed to crystallize.  
The crystals were isolated by filtration and  
dried *in vacuo* at room temperature. The  
product, which weighed 125 mg., contained  
7.5 per cent volatiles and assayed 86.5 per-  
cent Vitamin B—12 (anhydrous basis) by iso-  
tope dilution assay. When correction is made  
for ratio of the molecular weights of cyano-  
cobalamin and the glycine cobalamin the  
purity is ca. 90 per cent.

70

75

80

85

In a similar manner aspartic acid cobalamin  
is prepared by combining aspartic acid and  
hydroxocobalamin in aqueous solution and  
adding acetone.

Thus, in the treatment of pernicious anaemia,  
cyanocobalamin is administered parenterally by  
subcutaneous or intramuscular injections. For  
this purpose aqueous solutions of vitamin  
B—12 in suitable vehicles are used. However,  
improved forms of cobalamin which would  
provide higher serum levels of cobalamin have  
been sought.

It is an aim of the present invention to  
provide improved cobalamin products produc-  
ing higher serum levels of cobalamin on  
administration.

It has now been found that amino acid-  
cobalamins are valuable sources of cobalamin  
activity and possess the unexpected advantage  
that they are absorbed to a greater extent than  
cyanocobalamin. Thus, clinical tests show that  
these cobalamins give higher blood levels upon  
administration, and also apparently give higher  
prolonged serum levels of cobalamin.

There is therefore provided, according to  
the invention, a composition comprising an  
amino acid cobalamin and a pharmacologically  
acceptable carrier therefor.

The amino acid cobalamins are conveniently

**BEST AVAILABLE COPY**